- You can view the full GlaxoSmithKline Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
With sales of its hepatitis C drugs falling and an oncology pipeline that has largely disappointed, bictegravir is vitally important for Gilead to defend and grow its dominant HIV franchise.
With stocks at record highs, there are still buying opportunities, but investors should be selective.
GlaxoSmithKline beat analysts' expectations for fourth-quarter sales and earnings Wednesday but warned of a significant hit this year from anticipated generic competition to its Advair asthma treatment.